Skip to main content
LBP-22 Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial
Published Web Location
http://doi.org/10.1016/s0168-8278(23)00604-9No data is associated with this publication.